News

F. Randy Vogenberg, PhD, partner, Access Market Intelligence, and cofounder National Institute of Collaborative Healthcare, Greenville, S.C., shares insight from AMCP.

At AMCP 2016, presenters identified five types of alternative payment models, and shared why pharmacists play a key role.

Value-based pricing raises concerns when it comes to drug affordability and experts discuss a call to action saying “prices no longer reflect costs.”

Kaveh Safavi, senior managing director for consulting firm Accenture’s global healthcare business, shares how payer mergers will affect provider payments.

AMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching

: Providers and health plans aren’t the only industry groups affected by the shift to value-based care. It’s time for pharma to get in on the action.

An accurate account of your provider roster is essential to driving value-based care, according to one expert.

Study demonstrates how new technology can drive higher value healthcare for heart failure patients.

The generic metformin (Mallinkrodt) significantly reduced the risk of dying from heart attack and stroke compared to other common diabetes medications, according to a new study.

Greg Kennedy, research project manager with the ACO Research Team at the Dartmouth Institute for Healthcare Policy and Clinical Practice at Dartmouth College, shares recent ACO research findings.

A presenter at the AMCP Annual Meeting examines two different tools released by ASCO and NCCN and how a managed care organization utilizes these tools in the formulary review process.

Industry watchers weigh in on UnitedHealth Group’s announcement that it will exit all but a “handful” of state Affordable Care Act (ACA) exchanges.

At the AMCP Annual Meeting, three panelists shared real-world examples of technology that is improving patient engagement, adherence, and outcomes

At AMCP, four stakeholders representing the specialty pharmacy perspective, manufacturer perspective, payer perspective, and PBM perspective shared their thoughts on the future of specialty pharmacy.

FDA took the unusual step of withdrawing approval of two cholesterol-lowering drugs late last week.

Republican presidential candidate Donald Trump recently unveiled his 7-point healthcare plan. Find out more.

At the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.

To achieve scale economies, large hospitals and healthcare systems should shift toward integrated organizations with standardized procedures and systematically reduced costs.

The CEO of the Academy of Managed Care Pharmacy identifies key challenges and opportunities that will be discussed at the annual meeting.

A new report from IMS Institute for Healthcare Informatics finds that biosimilar acceptance will grow and drive change in the healthcare system.

Covered California adopts significant new changes to its contracts with health insurers as part of an aim to take health care reform to the next level.

Comprehensive Primary Care Plus (CPC+) advanced primary care medical home model aims to strengthen primary care through a regionally-based multipayer payment reform and care delivery transformation.

A new study explores the tangible effects of the ACA and the study author weighs in on the implications for managed care.

The death rate from overdoses involving benzodiazepines, a class of sedatives that includes Xanax, Valium, and Klonopin, has increased more than four-fold since 1996, according to a study appearing online in the American Journal of Public Health.

As organizations and politicians continue to sound the alarm that drug prices are rising, another new report confirmed the trend. Total spending on medicines in the US reached $310 billion in 2015 on an estimated net price basis, up 8.5 percent from the previous year, according to a new report from the IMS Institute for Healthcare Informatics.

Experts says UnitedHealthcare’s new boutique-style health plan is designed to drive innovation in primary care.

FDA advisory committee recently voted to recommend approval of obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis (PBC). If approved, Ocaliva would be the first new treatment for PBC in nearly 20 years.

FDA recently approved venetoclax (Venclexta, AbbVie and Genentech) to treat chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least 1 prior therapy

As a result of a recent case decided by the U.S. Supreme Court, advocates of healthcare transparency may need to adjust their data collection strategies.